Featured Story | | | Tuesday, August 22, 2017 Eli Lilly has secured an option on immune tolerance drugs from Evotec spinout Topas Therapeutics. The multiyear agreement positions Lilly to work with Topas on candidates that convey tolerance to antigens linked to inflammation or autoimmune diseases. |
|
|
| This week's sponsor is FierceBiotech Drug Development Forum. | | | Save 15% on the FierceBiotech 2nd Drug Development Forum
Network with 300+ biotech leaders and 90+ executive-level speakers at the largest biotech conference for optimizing pipeline strategies, partnerships and deal making September 25-27 in Boston, MA. Sign up today & save 15% w/ code C942FIERCE. |
Top Stories Tuesday, August 22, 2017 Krystal Biotech has filed to raise about $35 million in a Nasdaq IPO. The money will equip Krystal’s ex-Intrexon executive team to file an IND for its rare skin disease gene therapy in the first quarter of next year. Tuesday, August 22, 2017 Axial Biotherapeutics, which only formally came into being last November, has poached Srinivas G. Rao, M.D., Ph.D., from struggling DepoMed as its new chief medical officer. Tuesday, August 22, 2017 Encore Dermatology, formed two years ago as a vehicle for three ex-Valeant products, has picked up a late-stage pipeline drug via a deal with India's Dr. Reddy's Laboratories. Tuesday, August 22, 2017 Recently acquired Parexel has joined forces with the Osaka International Cancer Institute to help “drive greater efficiencies” across cancer and blood disease trials in Japan. Tuesday, August 22, 2017 BenevolentAI has hired Ian Churcher, D.Phil., from GlaxoSmithKline. The appointment of Churcher as VP of drug discovery furthers the secretive AI-enabled startup’s track record of poaching executives from Big Pharma. Tuesday, August 22, 2017 Make no mistake: FDA Commissioner Scott Gottlieb does not want to be associated with the anti-vaxxer movement. He resorted to Twitter on Monday to take a clear stand after press reports revealed a meeting between a top FDA official and Robert F. Kennedy Jr. | This week's sponsor is FierceBiotech. | | | FierceBiotech Executive Summit- London
Join FierceBiotech for our third annual Executive Summit in London. We'll gather the experts together to discuss innovation around R&D in the UK and look ahead to what's in store for 2018 with leaders in the field discussing trends in the industry. |
Resources Sponsored by: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored by: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored by: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. 2nd Strategic Partnerships for Drug Repurposing Oct 26-27 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London Hear from 130+ Experts Leading the Way in Life Science Marketing Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA |
